The global primary biliary cholangitis therapeutics market size was valued at US$732.5 million in 2023 and is projected to reach US$1358.1 billion by 2032, growing at a CAGR of 7.1% from 2024 to 2032.

After four months on the list, Mr Lawton received a transplant. "I got 10 minutes with my wife and kids so we just prayed ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Mirum Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLItm (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous ...

When his phone rang at 11.30pm on a winter’s night last year, organ transplant recipient David Wightman knew it could be a ...

Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical trial for ST-002, a novel drug candidate for patients ...